443 related articles for article (PubMed ID: 32283684)
1. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson RD; Flickinger JC; Snook AE
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
[TBL] [Abstract][Full Text] [Related]
2. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited.
Decker WK; Safdar A
Cytokine Growth Factor Rev; 2009 Aug; 20(4):271-81. PubMed ID: 19656718
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of gastric cancer: Past, future perspective and challenges.
Xie J; Fu L; Jin L
Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
[TBL] [Abstract][Full Text] [Related]
4. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.
Wiemann B; Starnes CO
Pharmacol Ther; 1994; 64(3):529-64. PubMed ID: 7724661
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal immunotherapy: historical perspectives and modern therapy.
Morano WF; Aggarwal A; Love P; Richard SD; Esquivel J; Bowne WB
Cancer Gene Ther; 2016 Nov; 23(11):373-381. PubMed ID: 27834358
[TBL] [Abstract][Full Text] [Related]
6. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy EF
Iowa Orthop J; 2006; 26():154-8. PubMed ID: 16789469
[TBL] [Abstract][Full Text] [Related]
7. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
Nakajima H; Nakatsura T
Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: Breakthrough or "deja vu, all over again"?
Sell S
Tumour Biol; 2017 Jun; 39(6):1010428317707764. PubMed ID: 28639883
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous regression: a hidden treasure buried in time.
Hoption Cann SA; van Netten JP; van Netten C; Glover DW
Med Hypotheses; 2002 Feb; 58(2):115-9. PubMed ID: 11812185
[TBL] [Abstract][Full Text] [Related]
10. Development of Cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cells and Their Role in Immunotherapy.
Gardner A; de Mingo Pulido Á; Ruffell B
Front Immunol; 2020; 11():924. PubMed ID: 32508825
[TBL] [Abstract][Full Text] [Related]
12. Dr William Coley and tumour regression: a place in history or in the future.
Hoption Cann SA; van Netten JP; van Netten C
Postgrad Med J; 2003 Dec; 79(938):672-80. PubMed ID: 14707241
[TBL] [Abstract][Full Text] [Related]
13. Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?
Zacharski LR; Sukhatme VP
J Thromb Haemost; 2005 Mar; 3(3):424-7. PubMed ID: 15748226
[No Abstract] [Full Text] [Related]
14. [Not Available].
Fridman WH
Bull Cancer; 2016 Nov; 103 Suppl 1():S122-S126. PubMed ID: 28057174
[TBL] [Abstract][Full Text] [Related]
15. [History of Immuno-therapy - from Coley Toxins to Check-points of the Immune Reaction].
Říhová B; Šťastný M
Klin Onkol; 2015; 28 Suppl 4():4S8-14. PubMed ID: 26647883
[TBL] [Abstract][Full Text] [Related]
16. Advances in strategies and methodologies in cancer immunotherapy.
Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
[TBL] [Abstract][Full Text] [Related]
17. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
Front Immunol; 2021; 12():714822. PubMed ID: 34367185
[TBL] [Abstract][Full Text] [Related]
18. Coley's toxin: historical perspective.
Bickels J; Kollender Y; Merinsky O; Meller I
Isr Med Assoc J; 2002 Jun; 4(6):471-2. PubMed ID: 12073431
[No Abstract] [Full Text] [Related]
19. [Cancer immunotherapy].
Kjeldsen JW; Donia M; Svane IM
Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of immunotherapy for the treatment of sarcoma.
Klemen ND; Kelly CM; Bartlett EK
J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
